Psychedelics: Therapeutic Agents or Not?
Thursday, September 25, 2025, 12:00 pm – 1:00 pm ET
Psychedelics are emerging as promising candidates in CNS drug development due to their sustained efficacy with infrequent dosing and favorable risk/benefit profiles in conditions such as depression, post-traumatic stress disorder, anxiety, and substance use disorders—areas of significant unmet need.
This webinar will provide an integrated overview of the scientific, regulatory, and translational landscape shaping the development of psychedelic-based therapeutics. Topics will include key nonclinical findings, the assessment of toxicity data to inform clinical trial design, and regulatory expectations for progressing through the FDA approval pathway. Additionally, the session will examine the realities of translating academic research into viable prescription therapeutics, with emphasis on what can feasibly be developed, approved, and adopted in real-world healthcare systems.
In particular, attendees will gain insights into approaches to assess and manage product-related risks based on information from the public domain and other acceptable sources, as as well as on conducting a risk/benefit analysis. These insights and others will be helpful in understanding perspectives that the speakers share on how psychedelic products may impact regulatory acceptance or commercial viability—including duration of effect, dosing paradigms, safety liabilities, product risk/benefit analysis, and the economic impact of treatment models.
Moderator
Kevin Murnane, PhD, LSU Health Shreveport
Marcus S. Delatte, PhD, Allucent
Speakers
Bob Discordia, PhD, EQUULUS Therapeutic
Realities for the Development and Commercialization of Psychedelic-Based Therapeutics
Kevin Murnane, PhD, LSU Health Shreveport
Psychedelics as Pharmacotherapeutic Agents for Stimulant Use Disorder
Marcus S. Delatte, PhD, Allucent
Psychedelics: Assessing and Managing Product Risks